Should Systemic Hormone Therapy Be Continued After Age 65?

A new statement from NAMS says yes.

Patterns of HT use changed markedly following the Women's Health Initiative (WHI) report that the risks of menopausal hormone therapy (HT) exceeded its benefits (JAMA 2002; 288:321) — but since then, several studies have suggested that the story is far more complicated and that HT is warranted in certain instances. In 2012, the North American Menopause Society (NAMS), noting that HT carries fewer risks in younger postmenopausal women, recommended the lowest possible dose for the shortest time necessary (generally <5 years; Menopause 2012; 19:257). Because many women experience vasomotor symptoms even after age 65, NAMS has recently issued a position statement that continuing HT past age 65 is acceptable provided the woman has been advised o…

Reviewing Author

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Should Systemic Hormone Therapy Be Continued After Age 65?

Topics

Reviewing Author